Keywords: 3b, early-stage, drug, discovery, market, faces, new
$3B early-stage drug discovery market faces new demands
Article | 19 July 2004
The market for tools and services in combinatorial chemistry andhigh-throughput screening approached $3 billion in 2003, but a dynamic set of challenges ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
